Frederik L Giesel1,2,3, Leon Will4, Claudia Kesch5, Martin Freitag2,6, Christophe Kremer4, Jonas Merkle4, Oliver C Neels7, Jens Cardinale7, Boris Hadaschik5, Markus Hohenfellner5, Klaus Kopka7, Uwe Haberkorn4,2, Clemens Kratochwil4. 1. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany frederik@egiesel.com. 2. Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. German Cancer Consortium (DKTK), Heidelberg, Germany. 4. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 5. Department of Urology, University Hospital Heidelberg, Heidelberg, Germany. 6. Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; and. 7. Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results: 18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
Biochemical recurrence (BCR) is a concern for prostate cancerpatients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results: 18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancerpatients with BCR.
Authors: Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Jeffrey P Leal; Takahiro Higuchi; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe Journal: J Nucl Med Date: 2018-09-06 Impact factor: 10.057
Authors: Christos Sachpekidis; A Afshar-Oromieh; K Kopka; D S Strauss; L Pan; U Haberkorn; A Dimitrakopoulou-Strauss Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-14 Impact factor: 9.236
Authors: Christopher Darr; Nina N Harke; Jan Philipp Radtke; Leubet Yirga; Claudia Kesch; Maarten R Grootendorst; Wolfgang P Fendler; Pedro Fragoso Costa; Christoph Rischpler; Christine Praus; Johannes Haubold; Henning Reis; Thomas Hager; Ken Herrmann; Ina Binse; Boris Hadaschik Journal: J Nucl Med Date: 2020-02-14 Impact factor: 10.057
Authors: Kambiz Rahbar; Ali Afshar-Oromieh; Robert Seifert; Stefan Wagner; Michael Schäfers; Martin Bögemann; Matthias Weckesser Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-20 Impact factor: 9.236
Authors: Marcin Czarniecki; Esther Mena; Liza Lindenberg; Marek Cacko; Stephanie Harmon; Jan Philipp Radtke; Frederick Giesel; Baris Turkbey; Peter L Choyke Journal: Transl Androl Urol Date: 2018-10
Authors: Frederik L Giesel; Karina Knorr; Fabian Spohn; Leon Will; Tobias Maurer; Paul Flechsig; Oliver Neels; Kilian Schiller; Horacio Amaral; Wolfgang A Weber; Uwe Haberkorn; Markus Schwaiger; Clemens Kratochwil; Peter Choyke; Vasko Kramer; Klaus Kopka; Matthias Eiber Journal: J Nucl Med Date: 2018-07-24 Impact factor: 10.057